Friedrich von Bohlen
Together with Dietmar Hopp and Christof Hettich, he co-founded dievini in 2005. Since then, he has held the role of Managing Partner of dievini. He also serves as the Chairman or as a Board Member of companies which are a part of the dievini portfolio.
Friedrich von Bohlen began his professional career in 1992 as a Project Manager in research & development at Fresenius AG, Bad Homburg, following which he was Assistant to the Chairman of the Supervisory Board of FAG Kugelfischer KGaA, Schweinfurt. He then served as CEO of Wasag Chemie AG, Essen. In 1997 he co-founded Lion Bioscience AG, Heidelberg (now Expedeon AG) which he served as CEO until 2004.
Currently he is Chairman of the Supervisory Board of Apogenix AG and Novaliq GmbH as well as Board member of AC Immune SA, CureVac AG, Immatics biotechnologies GmbH and Heidelberg Pharma AG.
Using an artificial intelligence approach proteona sheds new light on the interaction of mRNA and proteins in thousands of cells in every clinical sample enabling new insights into immunoncology and making new immuncell therapies possible. Proteona is a spin off from the lab of Gene Yeo at the National University of Singapore / UC San Diego as well as the A-Star Molecular Engineering Lab of Nobel Laureate Sydney Brenner. Previously Andreas has co-founded AYOXXA Biosystems and headed the translational proteomics company as CEO from 2009 to 2016 continuously expanding the company to 40 employees operating from three sites in Cologne Germany, Singapore and Boston. He raised more than 25 Mil USD in venture capital, built the overall strategy of the company and established partnerships with several multinational pharma companies and leading academic institutions.
Here is what you can expect for our Meetups throughout Europe:
- 2 fireside chats with awesome speakers (one local, one not)
- 120 maximum sign-up
- Free entry
- A new city in Europe every six weeks
- Free beers and snacks
- The unique Refresh vibe